Skip to main content
Journal ArticleOPEN ACCESS

Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease

  • Cannon C
  • Shah S
  • Dansky H
  • et al.
New England Journal of Medicine (2010) 363(25) 2406-2415
DOI: 10.1056/nejmoa1009744
707Citations
Citations of this article
333Readers
Mendeley users who have this article in their library.

Abstract

Anacetrapib is a cholesteryl ester transfer protein inhibitor that raises high-density lipoprotein (HDL) cholesterol and reduces low-density lipoprotein (LDL) cholesterol.

Cite

CITATION STYLE

APA

Cannon, C. P., Shah, S., Dansky, H. M., Davidson, M., Brinton, E. A., Gotto, A. M., … Barter, P. (2010). Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease. New England Journal of Medicine, 363(25), 2406–2415. https://doi.org/10.1056/nejmoa1009744

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free